Sage Journals: Discover world-class research

Abstract

Adolescents with substance use disorders often have co-morbid disruptive behaviour disorders, due to shared aetiology or bidirectional feedback. Such patients require a more nuanced assessment, as discussed in this editorial. Limited studies exist on the management of the comorbidity. Psychosocial interventions, especially those involving the family, are the most important.

Keywords

Attention deficit hyperactivity disorder Adolescent substance use Conduct disorder Disruptive behaviour disorders Oppositional defiant disorder.

The National Survey on Extent and Pattern of Substance Use in India revealed substantial current prevalence of adolescent substance use (opioids: 1.8%, alcohol: 1.3%, inhalants: 1.17%, cannabis: 0.9%).¹ Besides, across India, most people seeking addiction treatment had initiated the use in adolescence.² Globally, adolescent substance use is highly comorbid with disruptive behavioural disorders [DBDs, i.e., attention deficit hyperactivity disorder (ADHD), conduct disorder (CD), and oppositional defiant disorder (ODD)] (Table 1). In a meta-analysis, ADHD and ODD/CD increased the odds of subsequent addiction (OR = 2.27 and 3.18).¹⁹ Moreover, substance use is common even in those with subclinical behaviour problems.²⁰ Conversely, those with less severe substance use also have higher odds of ADHD symptoms and CD.¹⁹ The comorbidity is also associated with lower SUD treatment completion rates.^10,14

Table 1.

Comorbidity Rates of SUDs in Individual Disruptive Behaviour Disorders (DBD).

Disorder	Prevalence/Risk Statistics of DBD in SUD	Prevalence/Risk Statistics of SUD in DBD	SUD Risk in Prospective Studies	Associated Outcomes in Patients with Comorbidity
ADHD	•25.3% with SUD had ADHD (2011 meta-analysis).³•44.3% in a community sample.⁴•At least 25% have ADHD (2022 review).⁵	•Lifetime CUD in ADHD:⁶ 26.9%.•CD symptoms may mediate the higher substance use rates^7,8; however, higher nicotine, alcohol, and illicit drug use have been found independent of CD.⁵	•4 years: HR = 1.77 for SUD; HR = 8.61 for nicotine dependence (vs. healthy controls; higher in ADHD + CD).⁹•Earlier onset of SUD.¹⁰	•Lower SUD treatment completion rates compared to those without ADHD.³
CD*	•60.7% in males with SUD (community sample).⁴	•52% with CD had SUD.¹¹•1.7-fold higher odds for alcohol use; 1.4-fold for cannabis use (vs. other psychiatric diagnoses, inpatients).¹²	•Conduct problems/criminal behaviour at age 15 predict¹³ substance use at age 17.	•Higher likelihood of treatment non-completion.¹⁴•2-year follow-up: Improvements in criminality, CD, and ADHD; substance use largely unchanged. Earlier onset and higher severity of CD and dependence on more drugs predicted worse outcomes.¹⁵
ODD		•47.2% have SUD.¹⁶	•Number of ODD symptoms in early adolescence predicts higher later alcohol use.¹⁷

SUD: Substance use disorder; ADHD: Attention deficit hyperactivity disorder; CUD: Cannabis use disorder; CD: Conduct disorder; HR: Hazards ratio; ODD: Oppositional defiant disorder.

* A systematic review¹⁸ found the highest risk of SUD in children with concurrent ADHD and CD.

Thus, understanding how these conditions interact is central to prevention, assessment, and management. This editorial synthesises current evidence while emphasising pragmatic assessment and management strategies relevant to low-resource and Indian clinical settings.

Discussion

Aetiology of the Comorbidity

Two major mechanisms have been proposed:²¹

Shared Etiological Factors

A twin registry study found a shared genetic factor for childhood CD, alcohol/drug dependence, and adult antisocial behaviour.²² A combination of smaller grey matter volume and lower white matter integrity is associated with an increase in both impulsivity and early substance use risk. Also, altered functional connectivity in the inhibitory control and reward processing networks elevates the risk of both impulsivity and substance use.²³ Family (e.g., poor parental supervision), peer (e.g., early involvement with deviant peer groups), and community risk factors may also contribute to comorbidity.²⁴

Bidirectional Feedback

Substance use can worsen the DBD (e.g., cannabis may exacerbate aggression and antisocial behaviour).²⁵ Conversely, those with DBDs can use substances due to the symptoms or as self-medication. For example, ADHD symptoms may encourage involvement with deviant peers²⁴ and risk- and drug-seeking behaviours.⁵ While stimulants such as nicotine may temporarily ameliorate attentional deficits, alcohol and opiates may allay anxiety and excessive arousal.²⁶

Diagnostic Challenges

Diverse clinical problems and their consequences may be causing guilt, shame, stigma, and fear. Many patients have trauma histories with resultant trust issues.²¹ Hence, assessment and diagnosis should be ongoing and evolve across multiple sessions. Clinicians should differentiate experimentation from problematic use (e.g., functional impairment) and identify the underlying risk factors (e.g., positive vs. negative reinforcement processes).²⁷ However, high dropout rates between screening and diagnostic assessments and possible unreliable history may jeopardise the process.²⁸

Attention Deficit Hyperactivity Disorder

Symptoms like inattention, impulsivity, and executive dysfunction may be common to both ADHD and SUD.²⁸ Hence, ADHD evaluation is best conducted after a period of abstinence (e.g., one month) or detoxification or stabilisation from SUD.²⁹ However, this may be difficult in outpatients, as ADHD symptoms may hamper involvement with SUD treatment.²⁸ Also, ongoing cannabis use confoundsthe assessment of ADHD medications’ effectiveness on hyperactivity and inattention.³⁰

Oppositional Defiant Disorder/ Conduct Disorder

Irritability and aggression, prevalent in intoxication and withdrawal states and indistinguishable from baseline oppositional features, may complicate both diagnostic and therapeutic-response assessments.³¹ Illegal activities, such as stealing, may be aimed at procuring substances and not reflect a core CD symptom.³²

Rating Scales

Especially in busy, low-resource settings, nurses or counsellors may be trained to administer rating scales for a comprehensive assessment.³³ We³³ routinely use the Strengths and Difficulties Questionnaire,³⁴ Adverse Childhood Experiences-Questionnaire,³⁵ Teen Addiction Severity Index,³⁶ Adolescent Smoking Consequences Questionnaire,³⁷ and Parent/Teacher DBD Rating Scale.³⁸ Other tools for a multifaceted evaluation of substance use, mental health, strengths, and diverse life domains include Global Appraisal of Individual Needs Quick Version-4,³⁹ Problem Oriented Screening Instrument for Teenagers (POSIT),⁴⁰ and Comprehensive Adolescent Severity Inventory.⁴¹

Evidence-based Treatment

A recent review⁴² found only three randomised controlled trials (RCTs):

In adolescents with major depressive disorder, lifetime CD, and at least one non-tobacco SUD, fluoxetine + cognitive behaviour therapy (CBT) was not more effective on substance use or CD symptoms than placebo + CBT.⁴³

Osmotic-release methylphenidate + CBT was not more effective on ADHD or substance use than placebo + CBT.⁴⁴

Atomoxetine + motivational interviewing (MI)/CBT was not more effective than placebo + MI/CBT for ADHD or use of non-nicotine substances.⁴⁵

(Please remember that negative trials per se do not imply futility but may instead indicate the need for better-designed studies).

In secondary analysis of an RCT, in patients with a DBD and cannabis abuse/dependence receiving motivational enhancement therapy (MET), CBT, and abstinence contingency management, when family management training (FMT) or parent psychoeducation was additionally provided, the FMT group had fewer days of cannabis use; externalising behaviours did not change significantly. The FMT, 45 minutes long, included Parent Management Training (PMT) and the development and implementation of a substance-monitoring contract.⁴⁶

Nicotine patches and bupropion help ADHD symptoms, such as inattention.⁴⁷ However, in those with alcohol, cannabis, or opiate use disorder, ADHD medications have little impact on the SUD, despite improvement in ADHD symptoms.³⁰ Hence, a combination of both ADHD medications and SUD treatments is recommended for most patients with the comorbidity.⁴⁸ A systematic review found only four randomised trials of pharmacotherapy for co-morbid ADHD and SUD; none revealed a robust effect on either. No RCTs were found on the efficacy of psychosocial treatments in co-morbid ADHD and SUD.¹⁸

Practical Guidance from Literature

A biopsychosocial–spiritual approach is essential.²¹ Combined psychotherapeutic and pharmacological interventions are the most effective.⁴⁹ The spiritual component may emphasise wholeness, balance, and relationships with family, community, and the natural environment.²¹ As the multitude of symptoms often leads to poor adjustment to or expulsion from school and association with peers having similar vulnerabilities, educational and crime-prevention services may need to be involved.²¹

If the DBD diagnosis is uncertain, waiting for a period of sobriety before starting medication may provide a clearer picture. However, DBD medications may be introduced earlier in case of: (a) DBD symptoms clearly predating substance use; (b) past treatment failures and relapses; and (c) history of good medication response to DBD.²⁴

Attention Deficit Hyperactivity Disorder

As impulsivity may lead to early relapse, ADHD medication³⁰ and relapse-prevention strategies⁵⁰ may require quick initiation. Psychoeducation should emphasise the relative safety of ADHD medication even during ongoing substance use.²⁸ As ADHD patients may struggle in treatment settings due to their reduced ability to process new information (e.g., inattention or distractibility in a group setting), group leaders and participants should be sensitised to ADHD.²⁶ Likewise, role plays on specific skills that can be automatically applied, minimising cognitive load during real-life stressful situations, could be utilised.²⁸

Preventing Stimulant Misuse

A systematic review on misuse of prescribed stimulants among ADHD patients found no youth-specific studies; in studies that included both youth and adults, the prevalence ranged from 2% to 29%, with higher rates in those with a substance use history.⁵¹ Recommendations for prevention include:³⁰

Close monitoring for signs of misuse, such as missing appointments or requesting higher doses or more prescriptions.

Considering extended-release methyl-phenidate formulations, or non-stimulants such as atomoxetine or bupropion.

Conduct Disorder

The propensity for deviant social behaviour, which contributes heavily to overall dysfunction, should be addressed. Issues such as impulsivity, affective dysregulation, excessive anger, and poor social and problem-solving skills can be managed through behavioural interventions, including skills training and cognitive-behavioural methods. Promoting association with non-substance-using peers and adoption of prosocial activities and goals is essential, too.²⁴

Managing Individual Conditions

Given the limited evidence on management of the comorbidity, each disorder may be addressed with its most supported interventions:

Substance Use Disorder

Psychosocial interventions are the recommended primary modality; the most effective are family-based therapy, CBT, and multicomponent approaches that combine these interventions with MI and contingency management. Family-based therapies engage parents, caregivers, and siblings and are particularly effective in promoting therapeutic alliance and treatment attendance.⁵²

The only FDA-approved pharmacotherapy is buprenorphine for opioid use disorder (in those aged ≥16).⁵³ Digital therapies can complement other treatments to improve accountability and teach recovery-focused life skills.⁵⁴

‘Controlled use’ should never be an explicit treatment goal, though it can be an interim goal to help build skills to tackle substance use and improve self-efficacy.⁵⁵

Nicotine

Counselling received a strong recommendation, while varenicline and bupropion received conditional recommendations, both based on very low–certainty evidence. Nicotine replacement therapy has limited effectiveness.⁵⁶

Alcohol

Among psychosocial interventions, the highest effect sizes were noted for integrated MET-CBT in reducing the frequency, and for Common Elements Treatment Approaches in reducing the amount.⁵⁷

Cannabis

Contingent rewards, engaging the family, and brief motivational counselling that includes information on peer network⁵⁸ have shown promise.⁵⁹

Inhalants

Certain holistic, multifaceted residential programmes have the highest success rates. While small clinical trials support aripiprazole, case reports support baclofen, naltrexone, and lamotrigine. CBT-based brief interventions and family therapy have some supporting evidence.⁶⁰

Attention Deficit Hyperactivity Disorder

ADHD should be managed with an individualised multimodal approach incorporating psychoeducation, medication, and psychosocial interventions. In general, stimulants are recommended as first-line therapy and non-stimulants as second-line.⁶¹ In a subgroup analysis within a meta-analysis, for parent-rated symptoms, meta-analyses did not find stimulants to be significantly superior to non-stimulants. However, for teacher ratings, stimulants had a higher effect size (SMD: 0.79 vs. 0.42).⁶²

A systematic review of recent trials revealed that the effects of cognitive/behavioural treatments (C/BTs) and medication were complementary rather than duplicative. It advised combining medication and C/BT in the beginning itself, to enhance adherence and response breadth (i.e., improve both ADHD symptoms/cognitive performance and coping skills/functional impairments).⁶³

Stimulants are the first-line treatment for aggression in ADHD. However, many patients would require additional interventions. Clonidine may provide some benefit for conduct-related behaviours in ADHD patients.⁶⁴

Conduct Disorder/Oppositional Defiant Disorder

Atypical antipsychotics are relevant in DBDs because most vulnerability alleles are related to dopaminergic and serotonergic systems.⁶⁵ Of all antipsychotics, risperidone seems effective in the short-term management. However, antipsychotics are associated with weight gain in this population.⁶⁶

Psychosocial interventions are considered the most effective, particularly when they have multiple components and involve both the patient and parents.⁶⁷ However, even in high-income countries, up to 70% of children and adolescents do not receive these interventions when needed.⁶⁸ Moreover, several familial and social risk factors of DBDs (e.g., economic backwardness, parental unemployment or substance use) can themselves hinder engagement in psychosocial interventions.⁶⁹

Aggression

Risperidone and divalproex have the most evidence, with promising but less robust data available for other atypical antipsychotics such as aripiprazole. Lithium and haloperidol have shown efficacy, primarily in inpatients.⁶⁴

Trauma

CBTs with a trauma focus are the first-line treatment.⁷⁰ Inpatients, in particular, should receive trauma-informed care that emphasises safety, minimises re-traumatisation, helps rebuild a sense of empowerment, and highlights strengths and resilience.⁷¹

Prevention

Universal Prevention

Indian adolescents have poor knowledge of substance-related harms,⁷² and friends and close acquaintances are the commonest introducers to substances.⁷³ Drug awareness alone is ineffective; training in social skills, problem solving, and anger management may help prevent SUDs and later DBDs.²⁴ Relationship skills should be part of the school curriculum.³² As the usual age of starting tobacco use is about 12 years, interventions must be directed at younger age groups.⁷⁴ Using local images, incorporating cultural values, etc., can help culturally adapt the prevention efforts.⁷⁵

Educating teachers not only about substance use but also about issues such as conduct problems may be useful.⁷⁴ Supply reduction (e.g., a ban on the sale of legal substances to minors) should also be employed.³²

A review identified Functional Family Therapy, Positive Family Support, and Lifeskills Training as the programmes with the highest benefit-cost ratios in preventing adolescent substance use.⁷⁶

Selective Prevention

In high-risk adolescents, a programme with psychoeducational, MET, and CBT components reduced the substance use rates and related harms by about 50% and the likelihood of transitioning to psychological problems, including conduct problems, by 25%; effects lasted 2–3 years.⁷⁷ A group cognitive-behavioural intervention targeting impulsivity and sensation seeking reduced the growth in SUD rate for five years.⁷⁸

Unhealthy relationships augment the genetic influences on substance use. For example, lower parental monitoring increases the likelihood that genetic predispositions manifest.⁷⁹ Likewise, in adolescents with more peers who use alcohol, genetic predispositions had a greater expression.⁸⁰ These findings can inform tailored prevention for those with a family history.⁸¹

School counsellors should reach out to those with family risk factors, substance-using peers, or a history of stressful events. As most treatment-seeking Indian adolescents are school dropouts,⁷⁴ and substance use and externalising problems are risk factors for school dropout,⁸² vocational training centres and safe spaces should be made available to them.⁷⁴ Counselling services and interventions, such as life-skills-based education, should be provided in such places.⁷⁴

Indicated Prevention

Treatment of DBDs in childhood, including PMT, is crucial.²⁴ Family interventions should emphasise the importance of parental monitoring (i.e., knowing the child’s peers and whereabouts after school).⁸³ For those with DBDs, SUD prevention interventions should be of sufficient duration and intensity to promote durable change. Including booster or follow-up sessions may increase the likelihood of sustained change, foster resilience to SUD, and improve later DBD outcomes.²⁴ In children with ADHD, stimulants may prevent SUD in adolescence.¹⁸ Besides, ADHD interventions may make substance problems more treatment-responsive.²⁷

Mentorship programmes, effective in selective and indicated prevention of substance use and externalising problems independently,⁸⁴ need evaluation in co-morbid populations.

Indian Scenario

Research on comorbidity in India is sparse. Among 49 patients of addictive disorders at our centre (including 11 with gaming disorder), conduct-dissocial disorder, ADHD, and ODD were present in 22, 14, and 11, respectively.³³

Specialised substance treatment services for children or adolescents are restricted to a few centres. Many lack infrastructure and staff and function suboptimally.⁷⁴ Though the National Action Plan for Drug Demand Reduction funds one centre for adolescent boys in each state,⁸⁵ currently, only Delhi and Manipur run them. Even where services are available, treatment-seeking is poor, probably due to lack of motivation, stigma, or deficient understanding about the nature of SUDs.⁷⁴

The Mental Healthcare Act (MHCA) 2017 mandates that minors be admitted only with the nominated representative (NR) or an attendant appointed by the NR.⁸⁶ This poses practical challenges, especially when a short-term rehabilitation is required to manage both SUDs and DBDs. Besides, adolescents with addictive disorders often come from broken families^87,88 (57.6% in our study of 59 patients, of whom 79.7% had a DBD),⁸⁹ limiting bystander availability.

We developed a care model that low-resource settings can adopt for assessment and management of SUDs and DBDs. It included training social work postgraduates and nurses in the use of assessment tools and workbooks. The model was found to be feasible and acceptable to patients.³³

Conclusions

This critical area remains under-researched. Cultural validation of assessment tools and efficacy studies of interventions are urgently needed. Amendments to MHCA, with provision to admit at least patients from broken families or the street without a bystander, would ease rehabilitation efforts. Timely diagnosis and deployment of culturally appropriate, cost-effective, and empirically validated therapeutic and preventive interventions, alongside ongoing research and policy measures, can keep many dreams from ever needing a requiem.

Footnotes

Declaration of Conflicting Interests

The author declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Declaration Regarding the Use of Generative AI

During the preparation of this manuscript, the author used Grok 4.1, ChatGPT 5.2, and Perplexity Pro to assist with literature search and to improve the language and structure. ChatGPT 5.2 was also used to format the references, which the author subsequently reviewed and verified. No part of this article was written by a generative AI tool. The author takes full responsibility for the content of the published article.

Funding

The author received no financial support for the research, authorship and/or publication of this article.

References

Ambekar

, Agrawal

, Rao

, . Magnitude of substance use in India 2019. New Delhi: Ministry of Social Justice and Empowerment, Government of India, 2019. https://www.lgbrimh.gov.in/resources/Addiction_Medicine/elibrary/magnitude_substance_abuse_india.pdf (accessed 18 December 2025 ).

Ray

. National survey on extent, pattern and trends of drug abuse in India. New Delhi: Ministry of Social Justice and Empowerment and United Nations Office on Drugs and Crime, Regional Office for South Asia, 2004.

van Emmerik-van Oortmerssen

, van de Glind

, van den Brink

, . Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: A meta-analysis and meta-regression analysis. Drug Alcohol Depend, 2012; 122(1–2): 11–19. DOI: 10.1016/j.drugalcdep.2011.12.007.

Szobot

, Rohde

, Bukstein

, . Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case–control study. Addiction, 2007; 102(7): 1122–1130. DOI: 10.1111/j.1360-0443.2007.01850.x.

Köck

, Meyer

, Elsner

, . Co-occurring mental disorders in transitional-aged youth with substance use disorders: A narrative review. Front Psychiatry, 2022; 13: 827658. DOI: 10.3389/fpsyt.2022.827658.

Froude

, Fawcett

and Coles

. The prevalence of cannabis use disorder in attention-deficit hyperactivity disorder: A clinical epidemiological meta-analysis. J Psychiatr Res, 2024; 172: 391–401. DOI: 10.1016/j.jpsychires.2024.02.050.

Kim

and Kim

Behavioral symptoms of child mental disorders and lifetime substance use in adolescence: A within-family comparison of US siblings. Drug Alcohol Depend, 2021; 219: 108490. DOI: 10.1016/j.drugalcdep.2020.108490.

Heradstveit

, Askeland

and Bøe

. Substance-related problems in adolescents with ADHD diagnoses: The importance of self-reported conduct problems. J Atten Disord, 2022; 26(14): 1857–1869. DOI: 10.1177/10870547221105063.

Groenman

, Oosterlaan

, Rommelse

, . Substance use disorders in adolescents with attention deficit hyperactivity disorder: A 4-year follow-up study. Addiction, 2013; 108(8): 1503–1511. DOI: 10.1111/add.12188.

10.

Kroll

, Feldman

, Wang

, . The associations of comorbid substance use disorders and psychiatric conditions with adolescent brain structure and function: A review. J Neurol Sci, 2020; 418: 117099. DOI: 10.1016/j.jns.2020.117099.

11.

Reebye

, Moretti

and Lessard

. Conduct disorder and substance use disorder: Comorbidity in a clinical sample of preadolescents and adolescents. Can J Psychiatry, 1995; 40: 313–319.

12.

Masroor

, Patel

, Bhimanadham

, . Conduct disorder-related hospitalization and substance use disorders in American teens. Behav Sci (Basel), 2019; 9(7): 73. DOI: 10.3390/bs9070073.

13.

Jangard

, Olsson

, Molero

, . Antisocial and prosocial behaviors as predictors of subsequent substance use in adolescence. Addict Behav, 2025; 166: 108308. DOI: 10.1016/j.addbeh.2025.108308.

14.

Kaminer

, Tarter

, Bukstein

, . Comparison between treatment completers and non-completers among dually diagnosed substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry, 1992; 31: 1046–1049.

15.

Crowley

, Mikulich

, MacDonald

, . Substance-dependent, conduct-disordered adolescent males: Severity of diagnosis predicts 2-year outcome. Drug Alcohol Depend, 1998; 49(3): 225–237. DOI: 10.1016/S0376-8716(98)00016-7.

16.

Nock

, Kazdin

, Hiripi

, . Lifetime prevalence, correlates, and persistence of oppositional defiant disorder: Results from the National Comorbidity Survey Replication. J Child Psychol Psychiatry, 2007; 48(7): 703–713. DOI: 10.1111/j.1469-7610.2007.01733.x.

17.

White

, Xie

, Thompson

, . Psychopathology as a predictor of adolescent drug use trajectories. Psychol Addict Behav, 2001; 15(3): 210–218.

18.

Özgen

, Spijkerman

, Noack

, . Treatment of adolescents with concurrent substance use disorder and attention-deficit/hyperactivity disorder: A systematic review. J Clin Med, 2021; 10(17): 3908. DOI: 10.3390/jcm10173908.

19.

Groenman

, Janssen

TWP

and Oosterlaan

Childhood psychiatric disorders as risk factor for subsequent substance abuse: A meta-analysis. J Am Acad Child Adolesc Psychiatry, 2017; 56(7): 556–569. DOI: 10.1016/j.jaac.2017.05.004.

20.

Storr

, Accornero

and Crum

. Profiles of current disruptive behavior: Association with recent drug consumption among adolescents. Addict Behav, 2007; 32(2): 248–264. DOI: 10.1016/j.addbeh.2006.03.045.

21.

Otasowie

. Co-occurring mental disorder and substance use disorder in young people: etiology, assessment and treatment. BJPsych Adv, 2021; 27(4): 272–281. DOI: 10.1192/bja.2020.64.

22.

Kendler

, Prescott

, Myers

, . The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry, 2003; 60(9): 929–937. DOI: 10.1001/archpsyc.60.9.929.

23.

Green

, Meredith

, Mewton

, . Adolescent neurodevelopment within the context of impulsivity and substance use. Curr Addict Rep, 2023; 10(2): 166–177. DOI: 10.1007/s40429-023-00485-4.

24.

Bukstein

. Disruptive behavior disorders and substance use disorders in adolescents. J Psychoactive Drugs, 2000; 32(1): 67–79. DOI: 10.1080/02791072.2000.10400213.

25.

Blair

RJR

, Bashford-Largo

, Zhang

, . Alcohol and cannabis use disorder symptom severity, conduct disorder, and callous-unemotional traits and impairment in expression recognition. Front Psychiatry, 2021; 12: 714189. DOI: 10.3389/fpsyt.2021.714189.

26.

Sullivan

and Rudnik-Levin

. Attention deficit/hyperactivity disorder and substance abuse: Diagnostic and therapeutic considerations. Ann N Y Acad Sci, 2001; 931: 251–270. DOI: 10.1111/j.1749-6632.2001.tb05783.x.

27.

Lee

, Humphreys

, Flory

, . Prospective association of childhood attention-deficit/hyperactivity disorder and substance use and abuse/dependence: A meta-analytic review. Clin Psychol Rev, 2011; 31(3): 328–341. DOI: 10.1016/j.cpr.2011.01.006.

28.

Young

, Abbasian

, Al-Attar

, . Identification and treatment of individuals with attention-deficit/hyperactivity disorder and substance use disorder: An expert consensus statement. World J Psychiatry, 2023; 13(3): 84–112. DOI: 10.5498/wjp.v13.i3.84.

29.

Brown

. ADHD comorbidities: Handbook for ADHD complications in children and adults. 1st ed. Washington, DC: American Psychiatric Pub, 2009.

30.

Barbuti

, Maiello

, Spera

, . Challenges of treating ADHD with comorbid substance use disorder: Considerations for the clinician. J Clin Med, 2023; 12(9): 3096. DOI: 10.3390/jcm12093096.

31.

Marmorstein

and White

. Comorbidity with substance abuse. In: Lochman

and Matthys

(eds) The Wiley handbook of disruptive and impulse-control disorders. 2017. DOI: 10.1002/9781119092254.ch5.

32.

Kathiresan

and Gupta

. Editorial: Adolescent drug use in India: Emerging trends and the way forward. J Indian Assoc Child Adolesc Ment Health, 2025; 21(3): 203–207. DOI: 10.1177/2455328X251363657.

33.

Ameen

, Sanish

, Babu

, . Addictive behaviors in adolescent boys: Developing a low-cost care model in India. Indian J Psychol Med. Epub ahead of print 15 August 2025. DOI: 10.1177/02537176251358098.

34.

Goodman

. The Strengths and Difficulties Questionnaire: A research note. J Child Psychol Psychiatry, 1997; 38(5): 581–586.

35.

Felitti

, Anda

, Nordenberg

, . Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The adverse childhood experiences (ACE) study. Am J Prev Med, 1998; 14(4): 245–258. DOI: 10.1016/S0749-3797(98)00017-8.

36.

Kaminer

, Buckstein

and Tarter

. The Teen-Addiction Severity Index: Rationale and reliability. Int J Addict, 1991; 26(2): 219–226.

37.

Lewis-Esquerre

, Rodrigue

and Kahler

. Development and validation of an adolescent smoking consequences questionnaire. Nicotine Tob Res, 2005; 7(1): 81–90.

38.

Silva

, Alpert

, Pouget

, . A rating scale for disruptive behavior disorders, based on the DSM-IV item pool. Psychiatr Q, 2005; 76(4): 327–339.

39.

Welsh

, Durham

, Sitar

, . Diagnosing adolescent substance use and co-occurring disorders using the Global Appraisal of Individual Needs Quick Version-4. Psychiatr Res Clin Pract, 2024; 6(4): 143–150. DOI: 10.1176/appi.prcp.20230078.

40.

Problem-Oriented Screening Instrument for Teenagers. In: Fisher

and Roget

(eds) Encyclopedia of substance abuse prevention, treatment, & recovery. Thousand Oaks, CA: SAGE Publications, 2009. DOI: 10.4135/9781412964500.n247.

41.

Meyers

, McLellan

, Jaeger

, . The development of the Comprehensive Addiction Severity Index for Adolescents (CASI-A): An interview for assessing multiple problems of adolescents. J Subst Abuse Treat, 1995; 12(3): 181–193. DOI: 10.1016/0740-5472(95)00009-T.

42.

Marshall

, Reeson

, Loverock

, . Evidence-based interventions for youth with concurrent mental health and substance use disorders: A scoping review. Can J Psychiatry, 2025; 70(5): 347–371. DOI: 10.1177/07067437241300957.

43.

Riggs

, Mikulich-Gilbertson

, Davies

, . A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med, 2007; 161(11): 1026–1034. DOI: 10.1001/archpedi.161.11.1026.

44.

Riggs

, Winhusen

, Davies

, . Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry, 2011; 50(9): 903–914. DOI: 10.1016/j.jaac.2011.06.010.

45.

Thurstone

, Riggs

, Salomonsen-Sautel

, . Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry, 2010; 49(6): 573–582. DOI: 10.1016/j.jaac.2010.02.013.

46.

Ryan

, Stanger

, Thostenson

, . The impact of disruptive behavior disorder on substance use treatment outcome in adolescents. J Subst Abuse Treat, 2013; 44(5): 506–514. DOI: 10.1016/j.jsat.2012.11.003.

47.

van Amsterdam

, van der Velde

, Schulte

, . Causal factors of increased smoking in ADHD: A systematic review. Subst Use Misuse, 2018; 53(3): 432–445. DOI: 10.1080/10826084.2017.1334066.

48.

Perugi

, Pallucchini

, Rizzato

, . Pharmacotherapeutic strategies for the treatment of attention-deficit hyperactivity disorder with co-morbid substance-use disorder. Expert Opin Pharmacother, 2019; 20(3): 343–355. DOI: 10.1080/14656566.2018.1551878.

49.

Kelly

, Daley

and Douaihy

. Treatment of substance-abusing patients with co-morbid psychiatric disorders. Addict Behav, 2012; 37: 11–24.

50.

Levin

and Kleber

. Attention-deficit hyperactivity disorder and substance abuse: Relationships and implications for treatment. Harv Rev Psychiatry, 1995; 2(5): 246–258. DOI: 10.3109/10673229509017144.

51.

Callovini

, Janiri

, Segatori

, . Examining the myth of prescribed stimulant misuse among individuals with attention-deficit/hyperactivity disorder: A systematic review. Pharmaceuticals (Basel), 2024; 17(8): 1076. DOI: 10.3390/ph17081076.

52.

Fadus

, Squeglia

, Valadez

, . Adolescent substance use disorder treatment: An update on evidence-based strategies. Curr Psychiatry Rep, 2019; 21(10): 96. DOI: 10.1007/s11920-019-1086-0.

53.

Welsh

, Dopp

, Durham

, . Narrative review: Revised principles and practice recommendations for adolescent substance use treatment and policy. J Am Acad Child Adolesc Psychiatry, 2025; 64(2): 123–142. DOI: 10.1016/j.jaac.2024.03.010.

54.

, Edwards

, Shah

, . Exploring digital-based therapies for adolescents with substance use disorders: A brief literature review. J Indian Assoc Child Adolesc Ment Health, 2024; 20(2): 91–96. DOI: 10.1177/09731342241248896.

55.

Bukstein

, Bernet

, Arnold

, . Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry, 2005; 44(6): 609–621. DOI: 10.1097/01.chi.0000159135.33706.37.

56.

Beis

, Dimou

, Kotoulas

, . Nicotine replacement therapy as a smoking cessation tool for adolescents: An update. Front Psychiatry, 2025; 16: 1525510. DOI: 10.3389/fpsyt.2025.1525510.

57.

Belay

, Mak

, Wong

FKY

, . Psychosocial treatment options for adolescents and young adults with alcohol use disorder: Systematic review and meta-analysis. Front Public Health, 2024; 12: 1371497. DOI: 10.3389/fpubh.2024.1371497.

58.

Mason

, Sabo

and Zaharakis

. Peer network counseling as brief treatment for urban adolescent heavy cannabis users. J Stud Alcohol Drugs, 2017; 78(1): 152–157. DOI: 10.15288/jsad.2017.78.152.

59.

Ghafouri

, Correa da Costa

, Zare

Dehnavi A

, . Treatments for cannabis use disorder across the lifespan: A systematic review. Brain Sci, 2024; 14(3): 227. DOI: 10.3390/brainsci14030227.

60.

Lail

, Cornelio

, Go

, . Treatments for inhalant and volatile substance misuse: A scoping review. Cureus, 2025; 17(7): e89170. DOI: 10.7759/cureus.89170.

61.

Mechler

, Banaschewski

, Hohmann

, . Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther, 2022; 230: 107940. DOI: 10.1016/j.pharmthera.2021.107940.

62.

Türk

, Korfmacher

, Gerger

, . Interventions for ADHD in childhood and adolescence: A systematic umbrella review and meta-meta-analysis. Clin Psychol Rev, 2023; 102: 102271. DOI: 10.1016/j.cpr.2023.102271.

63.

Sibley

, Flores

, Murphy

, . Research review: Pharmacological and non-pharmacological treatments for adolescents with attention deficit/hyperactivity disorder: A systematic review of the literature. J Child Psychol Psychiatry, 2025; 66(1): 132–149. DOI: 10.1111/jcpp.14056.

64.

Stepanova

, Langfus

, Blair

, . Treating pediatric aggressive behaviors and comorbid conditions. Expert Opin Pharmacother, 2025; 26(6): 695–705. DOI: 10.1080/14656566.2025.2487157.

65.

Weeland

, Overbeek

, de Castro

, . Underlying mechanisms of gene–environment interactions in externalizing behavior: A systematic review and search for theoretical mechanisms. Clin Child Fam Psychol Rev, 2015; 18: 413–442.

66.

Rajkumar

. Antipsychotics in the management of disruptive behavior disorders in children and adolescents: An update and critical review. Biomedicines, 2022; 10(11): 2818. DOI: 10.3390/biomedicines10112818.

67.

Boldrini

, Ghiandoni

, Mancinelli

, . Systematic review and meta-analysis: Psychosocial treatments for disruptive behavior symptoms and disorders in adolescence. J Am Acad Child Adolesc Psychiatry, 2023; 62(2): 169–189. DOI: 10.1016/j.jaac.2022.05.002.

68.

Waddell

, Schwartz

, Andres

, . Fifty years of preventing and treating childhood behavior disorders: A systematic review to inform policy and practice. Evid Based Ment Health, 2018; 21: 45–52.

69.

Kolko

, Campo

, Kelleher

, . Improving access to care and clinical outcome for pediatric behavioral problems: A randomized trial of a nurse-administered intervention in primary care. J Dev Behav Pediatr, 2010; 31: 393–404.

70.

de Haan

, Meiser-Stedman

, Landolt

, . Efficacy and moderators of efficacy of cognitive behavioral therapies with a trauma focus in children and adolescents: an individual participant data meta-analysis of randomized trials. Lancet Child Adolesc Health, 2024; 8(1): 28–39. DOI: 10.1016/S2352-4642(23)00253-5.

71.

Fialkowski

, Shaffer

, Ball-Burack

, . Trauma-informed care for hospitalized adolescents. Curr Pediatr Rep, 2022; 10(2): 45–54. DOI: 10.1007/s40124-022-00262-3.

72.

Garg

, Sidhu

, Goel

, . An online survey of knowledge, attitude, and prevalence of substance use in school-going adolescents of a regional area of Punjab, India. J Indian Assoc Child Adolesc Ment Health, 2025; 21(1): 81–87. DOI: 10.1177/09731342241305499.

73.

Excise Department, Government of Kerala. An analysis of the causes and consequences of drug addiction and illegal drug trafficking among adolescents. Survey report 2020–2021. Published online 2022. https://keralaexcise.gov.in/wp-content/uploads/2023/03/Vimukthi-Survey-Report.pdf (accessed 18 December 2025 ).

74.

Dhawan

, Pattanayak

, Chopra

, . Pattern and profile of children using substances in India: Insights and recommendations. Natl Med J India, 2017; 30(4): 224–229. DOI: 10.4103/0970-258X.218679.

75.

Corpus-Espinosa

, Fadden

, Torrejón-Guirado

MDC

, . Exploring cultural adaptations: A scoping review on adolescent mental health and substance use prevention programs. Prev Sci, 2025; 26: 204–221. DOI: 10.1007/s11121-025-01779-x.

76.

Hsiung

, Patel

, Hundal

, . Preventing substance abuse in adolescents: A review of high-impact strategies. Cureus, 2022; 14(7): e27361. DOI: 10.7759/cureus.27361.

77.

Edalati

and Conrod

. A review of personality-targeted interventions for prevention of substance misuse and related harm in community samples of adolescents. Front Psychiatry, 2019; 9: 770. DOI: 10.3389/fpsyt.2018.00770.

78.

Conrod

, Stewart

, Seguin

, . Five-year outcomes of a school-based personality-focused prevention program on adolescent substance use disorder: A cluster randomized trial. Am J Psychiatry, 2025; 182(5): 473–482. DOI: 10.1176/appi.ajp.20240042.

79.

Dick

, Viken

, Purcell

, . Parental monitoring moderates the importance of genetic and environmental influences on adolescent smoking. J Abnorm Psychol, 2007; 116(1): 213–218. DOI: 10.1037/0021-843X.116.1.213.

80.

Marshal

and Chassin

Peer influence on adolescent alcohol use: The moderating role of parental support and discipline. Appl Dev Sci, 2000; 4: 80–88.

81.

Meyers

and Dick

. Genetic and environmental risk factors for adolescent-onset substance use disorders. Child Adolesc Psychiatr Clin N Am, 2010; 19(3): 465–477. DOI: 10.1016/j.chc.2010.03.013.

82.

Gubbels

, van der Put

and Assink

Risk factors for school absenteeism and dropout: a meta-analytic review. J Youth Adolesc, 2019; 48(9): 1637–1667. DOI: 10.1007/s10964-019-01072-5.

83.

Fletcher

, Darling

and Steinberg

Parental monitoring and peer influences on adolescent substance use. Pediatrics, 1994; 93(6 Pt 2): 1060–1064.

84.

Tolan

, Henry

, Schoeny

, . Mentoring programs to affect delinquency and associated outcomes of youth at-risk: A comprehensive meta-analytic review. J Exp Criminol, 2014; 10(2): 179–206. DOI: 10.1007/s11292-013-9181-4.

85.

Department of Social Justice & Empowerment. Scheme of national action plan for drug demand reduction (NAPDDR). 2023. https://socialjustice.gov.in/writereaddata/UploadFile/50491734426028.pdf (2023, accessed 18 December 2025 ).

86.

Government of India. The mental healthcare act, 2017. New Delhi: Ministry of Law and Justice, 2017. Available from: https://www.indiacode.nic.in/handle/123456789/2249 (2023, accessed 22 December 2025 ).

87.

Rakić

, Rakić

, Milošević

, . The prevalence of substance use among adolescents and its correlation with social and demographic factors. Vojnosanit Pregl, 2014; 71: 467–473.

88.

Pourmovahed

, Mahmoodabad

, Ardekani

, . Family structure in association with alcohol use among adolescents: A systematic review and meta-analysis. Int J High Risk Behav Addict, 2022; 11(1): e112404.

89.

Ameen

, Sanish

, Joseph

, . Adolescent boys with addictive disorders in an Indian rehabilitation centre: Profiles and correlates. Indian J Psychiatry, 2026; In Press.

Requiem for Many Dreams? Comorbid Substance Use and Disruptive Behaviour Disorders in Adolescents

Abstract

Keywords

Discussion

Aetiology of the Comorbidity

Shared Etiological Factors

Bidirectional Feedback

Diagnostic Challenges

Attention Deficit Hyperactivity Disorder

Oppositional Defiant Disorder/ Conduct Disorder

Rating Scales

Evidence-based Treatment

Practical Guidance from Literature

Attention Deficit Hyperactivity Disorder

Preventing Stimulant Misuse

Conduct Disorder

Managing Individual Conditions

Substance Use Disorder

Nicotine

Alcohol

Cannabis

Inhalants

Attention Deficit Hyperactivity Disorder

Conduct Disorder/Oppositional Defiant Disorder

Aggression

Trauma

Prevention

Universal Prevention

Selective Prevention

Indicated Prevention

Indian Scenario

Conclusions

Footnotes

Declaration of Conflicting Interests

Declaration Regarding the Use of Generative AI

Funding

References